Daver N et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol 2022;40(35):4048-59. Abstract
DiNardo CD et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378(25):2386-98. Abstract
Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract
Gupta V et al. Safety and efficacy of fedratinib in patients with primary (p), post-polycythemia vera (post-PV), and post-essential thrombocythemia (post-ET) myelofibrosis (MF) previously treated with ruxolitinib: Primary analysis of the FREEDOM trial. ASH 2022;Abstract 1711.
Harrison CN et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020;95(6):594-603. Abstract
Komrokji RS et al. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Adv 2023;[Online ahead of print]. Abstract
Mascarenhas J et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-9. Abstract
Mesa RA et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. ASCO 2022;Abstract 7002.
Mesa R et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 2022;36(9):2261-8. Abstract
Pardanani A et al. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol 2021;195(2):244-8. Abstract
Perl AE et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022;139(23):3366-75. Abstract
Pratz KW et al. Long-term follow-up of the phase 3 Viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. ASH 2022;Abstract 219.
Roboz GJ et al. Azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood 2022;139(14):2145-55. Abstract
Roboz GJ et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood 2020;135(7):463-71. Abstract
Santini V et al. Overall survival and progression-free survival of patients following luspatercept treatment in the MEDALIST trial. ASH 2022;Abstract 1774.
Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130(6):722-31. Abstract
Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401(10373):269-80. Abstract
Verstovsek S et al. Momelotinib (MMB) long-term safety: Pooled data from three phase 3 randomized-controlled trials (RCTs). ASH 2022;Abstract 4348.
Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017;10(1):156. Abstract
Wei AH et al. Long-term overall survival (OS) with oral azacitidine (oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC): Updated results from the phase 3 QUAZAR AML-001 trial. ASH 2021;Abstract 871.
Zeidan AM et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes. ASCO 2021;Abstract TPS7054.